- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07795164
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (PERFORMA)
A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Shaheen Tomah, MD
- Telefonnummer: 240-235-0145
- E-post: performa@altimmune.com
Studieorter
-
-
Alabama
-
Dothan, Alabama, Förenta staterna, 36301
- Rekrytering
- Altimmune Clinical Study Site
-
-
Arizona
-
Chandler, Arizona, Förenta staterna, 85224
- Rekrytering
- Altimmune Clinical Study Site
-
Tucson, Arizona, Förenta staterna, 85712
- Rekrytering
- Altimmune Clinical Study Site
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72205
- Rekrytering
- Altimmune Clinical Study Site
-
North Little Rock, Arkansas, Förenta staterna, 72117
- Rekrytering
- Altimmune Clinical Study Site
-
-
California
-
Fountain Valley, California, Förenta staterna, 92708
- Rekrytering
- Altimmune Clinical Study Site
-
Fresno, California, Förenta staterna, 93720
- Rekrytering
- Altimmune Clinical Study Site
-
Gardena, California, Förenta staterna, 90247
- Rekrytering
- Altimmune Clinical Study Site
-
Huntington Park, California, Förenta staterna, 90255
- Rekrytering
- Altimmune Clinical Study Site
-
La Mesa, California, Förenta staterna, 91942
- Rekrytering
- Altimmune Clinical Study Site
-
Long Beach, California, Förenta staterna, 90815
- Rekrytering
- Altimmune Clinical Study Site
-
Orange, California, Förenta staterna, 92866
- Rekrytering
- Altimmune Clinical Study Site
-
Orange, California, Förenta staterna, 92868
- Rekrytering
- Altimmune Clinical Study Site
-
Poway, California, Förenta staterna, 92064
- Rekrytering
- Altimmune Clinical Study Site
-
Van Nuys, California, Förenta staterna, 91405
- Rekrytering
- Altimmune Clinical Study Site
-
-
Colorado
-
Englewood, Colorado, Förenta staterna, 80113
- Rekrytering
- Altimmune Clinical Study Site
-
-
Florida
-
Boca Raton, Florida, Förenta staterna, 33434
- Rekrytering
- Altimmune Clinical Study Site
-
Bradenton, Florida, Förenta staterna, 34209
- Rekrytering
- Altimmune Clinical Study Site
-
Miami, Florida, Förenta staterna, 33173
- Rekrytering
- Altimmune Clinical Study Site
-
Miami, Florida, Förenta staterna, 33122
- Rekrytering
- Altimmune Clinical Study Site
-
Miami Lakes, Florida, Förenta staterna, 33016
- Rekrytering
- Altimmune Clinical Study Site
-
Ocala, Florida, Förenta staterna, 34471
- Rekrytering
- Altimmune Clinical Study Site
-
Orlando, Florida, Förenta staterna, 32803
- Rekrytering
- Altimmune Clinical Study Site
-
Port Orange, Florida, Förenta staterna, 32127
- Rekrytering
- Altimmune Clinical Study Site
-
-
Georgia
-
Dalton, Georgia, Förenta staterna, 30720
- Rekrytering
- Altimmune Clinical Study Site
-
-
Indiana
-
South Bend, Indiana, Förenta staterna, 46635
- Rekrytering
- Altimmune Clinical Study Site
-
-
Louisiana
-
Bastrop, Louisiana, Förenta staterna, 71220
- Rekrytering
- Altimmune Clinical Study Site
-
Marrero, Louisiana, Förenta staterna, 70072
- Rekrytering
- Altimmune Clinical Study Site
-
Monroe, Louisiana, Förenta staterna, 71201
- Rekrytering
- Altimmune Clinical Study Site
-
-
Maryland
-
Laurel, Maryland, Förenta staterna, 20708
- Rekrytering
- Altimmune Clinical Study Site
-
-
Massachusetts
-
New Bedford, Massachusetts, Förenta staterna, 02740
- Rekrytering
- Altimmune Clinical Study Site
-
-
Missouri
-
Columbia, Missouri, Förenta staterna, 65201
- Rekrytering
- Altimmune Clinical Study Site
-
Kansas City, Missouri, Förenta staterna, 64131
- Rekrytering
- Altimmune Clinical Study Site
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87107
- Rekrytering
- Altimmune Clinical Study Site
-
-
North Carolina
-
Fayetteville, North Carolina, Förenta staterna, 28304
- Rekrytering
- Altimmune Clinical Study Site
-
-
Ohio
-
Brooklyn, Ohio, Förenta staterna, 44144
- Rekrytering
- Altimmune Clinical Study Site
-
Springboro, Ohio, Förenta staterna, 45066
- Rekrytering
- Altimmune Clinical Study Site
-
Westlake, Ohio, Förenta staterna, 44145
- Rekrytering
- Altimmune Clinical Study Site
-
-
Rhode Island
-
East Greenwich, Rhode Island, Förenta staterna, 02818
- Rekrytering
- Altimmune Clinical Study Site
-
-
Texas
-
Austin, Texas, Förenta staterna, 78757
- Rekrytering
- Altimmune Clinical Study Site
-
Bellaire, Texas, Förenta staterna, 77401
- Rekrytering
- Altimmune Clinical Study Site
-
Brownsville, Texas, Förenta staterna, 78520
- Rekrytering
- Altimmune Clinical Study Site
-
Corpus Christi, Texas, Förenta staterna, 78404
- Rekrytering
- Altimmune Clinical Study Site
-
Dallas, Texas, Förenta staterna, 75230
- Rekrytering
- Altimmune Clinical Study Site
-
Edinburg, Texas, Förenta staterna, 78539
- Rekrytering
- Altimmune Clinical Study Site
-
Farmers Branch, Texas, Förenta staterna, 75234
- Rekrytering
- Altimmune Clinical Study Site
-
Forney, Texas, Förenta staterna, 75126
- Rekrytering
- Altimmune Clinical Study Site
-
Fort Worth, Texas, Förenta staterna, 76104
- Rekrytering
- Altimmune Clinical Study Site
-
Georgetown, Texas, Förenta staterna, 78626
- Rekrytering
- Altimmune Clinical Study Site
-
Houston, Texas, Förenta staterna, 77004
- Rekrytering
- Altimmune Clinical Study Site
-
Houston, Texas, Förenta staterna, 77079
- Rekrytering
- Altimmune Clinical Study Site
-
Kingwood, Texas, Förenta staterna, 77339
- Rekrytering
- Altimmune Clinical Study Site
-
Pasadena, Texas, Förenta staterna, 77505
- Rekrytering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Förenta staterna, 78215
- Rekrytering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Förenta staterna, 78209
- Rekrytering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Förenta staterna, 78229
- Rekrytering
- Altimmune Clinical Study Site
-
Sugar Land, Texas, Förenta staterna, 77479
- Rekrytering
- Altimmune Clinical Study Site
-
Waco, Texas, Förenta staterna, 76710
- Rekrytering
- Altimmune Clinical Study Site
-
-
Utah
-
Ogden, Utah, Förenta staterna, 84405
- Rekrytering
- Altimmune Clinical Study Site
-
West Jordan, Utah, Förenta staterna, 84088
- Rekrytering
- Altimmune Clinical Study Site
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Rekrytering
- Altimmune Clinical Study Site
-
-
-
-
Puerto Rico
-
San Juan, Puerto Rico, Puerto Rico, 00927
- Rekrytering
- Altimmune Clinical Study Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
All subjects:
- No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
- Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
- Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
- Subject agrees to have liver biopsy(ies) as required per protocol
Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening
Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing
Exclusion Criteria:
- Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
- Uncontrolled T2D or clinically significant persistent hyperglycemia
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
|
Placebo SC Injection |
|
Experimentell: Pemvidutid 2,4 mg
|
Pemvidutide SC Injection |
|
Experimentell: Pemvidutide 1.8 mg
|
Pemvidutide SC Injection |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Clinical Outcome Event
Tidsram: Baseline through end of study (approximately Month 60)
|
Time to first occurrence of any of the following events through the end of the study: Histologic progression to cirrhosis (F4) on liver biopsy; Liver related events; Liver transplantation; or Death due to any cause |
Baseline through end of study (approximately Month 60)
|
|
Histological Response: MASH resolution
Tidsram: Baseline through Week 52
|
Proportion of subjects achieving MASH resolution (according to NASH Clinical Research Network [CRN] classification) without worsening of fibrosis |
Baseline through Week 52
|
|
Histological Response: Fibrosis improvement
Tidsram: Baseline through Week 52
|
Proportion of subjects achieving ≥ 1 stage improvement in liver fibrosis according to the NASH CRN fibrosis staging system without worsening of MASH |
Baseline through Week 52
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH
Tidsram: Baseline through Week 52
|
Baseline through Week 52
|
|
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis
Tidsram: Baseline through Week 52
|
Baseline through Week 52
|
|
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)
Tidsram: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)
Tidsram: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)
Tidsram: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)
Tidsram: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score
Tidsram: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan
Tidsram: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.
Tidsram: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.
Tidsram: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.
Tidsram: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- ALT-801-301
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .